Search company, investor...

Predict your next investment

Boehringer Ingelheim Venture Fund company logo
Corporate Venture
boehringer-ingelheim-venture.com

Investments

89

Portfolio Exits

9

Funds

1

Partners & Customers

1

About Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund will be seeking to provide initial investments in seed or series A funding. Opening investments of up to €2 million per venture will be made at the early stage with subsequent staged investments made to align with each venture's progress, up to a total of €10-15 million per venture over its life.

Headquarters Location

Binger Strasse 173

Ingelheim am Rhein, D-55216,

Germany

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Boehringer Ingelheim Venture Fund News

T3 Pharma acquired by Boehringer Ingelheim for CHF 450 Million to strengthen immuno-oncology portfolio

Nov 23, 2023

23.11.2023 09:48, Rita Longobardi In a strategic move to fortify its position in the rapidly evolving field of immuno-oncology, Boehringer Ingelheim has successfully acquired T3 Pharma, a leading Swiss biotech company specializing in bacterial cancer therapy. The acquisition, valued at up to CHF 450 million, represents a significant expansion of T3 Pharma's innovating technology, which employs live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments. Boehringer Ingelheim seeks to significantly increase the 15-20% remission rate in cancer patients by employing diverse immuno-oncology platforms, including T-cell engagers, oncolytic viruses, and cancer vaccines. These complementary approaches aim to transform cold tumors into hot ones, expanding the benefits of immunotherapy to a broader patient base. T3 Pharma 's innovative technology adds to Boehringer Ingelheim's arsenal of immune-modulatory cancer treatments, aligning with the company's commitment to revolutionize cancer care. CEO Simon Ittig expresses excitement about integrating T3 Pharma's bacterial delivery platform, foreseeing accelerated development to combat solid cancers effectively: “We are extremely proud of the work of T3 Pharma’s team and very excited to continue and accelerate the successful development of our bacterial delivery platform as part of Boehringer Ingelheim. Being integrated with our partners at Boehringer will enable us to realize the full potential of our platform to fight solid cancers.” Utilizing engineered Yersinia enterocolitica bacteria, T3 Pharma's exclusive platform selectively delivers bioactive proteins to the tumor micro-environment, sparing healthy tissues. The bacteria can carry multiple immune-modulatory proteins, facilitating the design of combination therapies within a single agent. Boehringer Ingelheim's comprehensive cancer therapy approach combines cell-directed and immuno-oncology strategies. This approach seeks to create intelligent combinations for life-changing and best-in-class treatments. The company actively engages with emerging science, collaborates with a global network of academic and industry leaders, and invests in startups through initiatives like the Boehringer Ingelheim Venture Fund, a key investor in T3 Pharma. T3 Pharma was ranked among the  TOP 100 Swiss Startups in 2017, 2019, and 2020, as well as the TOP 100 Scale-ups in 2021. T3 Pharma's team: Dr. Christoph A. Kasper (Chief Scientific Officer), Dr. Claire Barton (Chief Medical Officer), and Dr. Simon J. Ittig (CEO) T3 Pharmaceuticals AG: Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-o... Read more Categories

Boehringer Ingelheim Venture Fund Investments

89 Investments

Boehringer Ingelheim Venture Fund has made 89 investments. Their latest investment was in Glox Therapeutics as part of their Seed VC on November 11, 2023.

CBI Logo

Boehringer Ingelheim Venture Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/14/2023

Seed VC

Glox Therapeutics

$5.28M

Yes

3

8/30/2023

Series B

Otto

$43M

No

4

7/6/2023

Series A - II

Actym Therapeutics

$25.5M

No

4

5/23/2023

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

5/10/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/14/2023

8/30/2023

7/6/2023

5/23/2023

5/10/2023

Round

Seed VC

Series B

Series A - II

Seed VC

Series A

Company

Glox Therapeutics

Otto

Actym Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$5.28M

$43M

$25.5M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

4

4

10

10

Boehringer Ingelheim Venture Fund Portfolio Exits

9 Portfolio Exits

Boehringer Ingelheim Venture Fund has 9 portfolio exits. Their latest portfolio exit was T3 Pharmaceuticals on November 22, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/22/2023

Acquired

$99M

6

12/10/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/10/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/18/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/22/2023

12/10/2020

7/15/2019

6/10/2019

4/18/2019

Exit

Acquired

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Boehringer Ingelheim Venture Fund Fund History

1 Fund History

Boehringer Ingelheim Venture Fund has 1 fund, including Boehringer Ingelheim Venture Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/3/2018

Boehringer Ingelheim Venture Fund I

$300.64M

2

Closing Date

1/3/2018

Fund

Boehringer Ingelheim Venture Fund I

Fund Type

Status

Amount

$300.64M

Sources

2

Boehringer Ingelheim Venture Fund Partners & Customers

1 Partners and customers

Boehringer Ingelheim Venture Fund has 1 strategic partners and customers. Boehringer Ingelheim Venture Fund recently partnered with Hong Kong Science and Technology Parks Corporation on June 6, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

6/17/2022

Partner

Hong Kong

HKSTP and Boehringer Ingelheim Venture Fund Launch Co-Incubation Programme to Fast-track R&D in Infectious Diseases and Immunology

This partnership between Hong Kong Science and Technology Parks Corporation and BIVF marks a key milestone to drive the Hong Kong 's biomedical technology development .

3

Date

6/17/2022

Type

Partner

Business Partner

Country

Hong Kong

News Snippet

HKSTP and Boehringer Ingelheim Venture Fund Launch Co-Incubation Programme to Fast-track R&D in Infectious Diseases and Immunology

This partnership between Hong Kong Science and Technology Parks Corporation and BIVF marks a key milestone to drive the Hong Kong 's biomedical technology development .

Sources

3

Boehringer Ingelheim Venture Fund Team

1 Team Member

Boehringer Ingelheim Venture Fund has 1 team member, including current Senior Director, James Kasuboski.

Name

Work History

Title

Status

James Kasuboski

BridgeBio, Apple Tree Partners, SV Health Investors, Pfizer, The Salk Institute for Biological Studies, and University of Notre Dame

Senior Director

Current

Name

James Kasuboski

Work History

BridgeBio, Apple Tree Partners, SV Health Investors, Pfizer, The Salk Institute for Biological Studies, and University of Notre Dame

Title

Senior Director

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.